Zobrazeno 1 - 10
of 851
pro vyhledávání: ''
Autor:
Jinying Shen, Yujie Zhao, Linhai Zhong, Tianhui Hu, Xiong Chen, Xiaolin Xu, Daxuan Wang, Yan-yan Zhan, Xiaoting Hong, Hanwei Cao, Yitong Zhou, Jianben Wu, Ying Lin, Wenqing Zhang, Jihuan Hou
Publikováno v:
Cancer Research. 81:5904-5918
Invasive mucinous lung adenocarcinoma (IMA) is a subtype of lung adenocarcinoma with a strong invasive ability. IMA frequently carries "undruggable" KRAS mutations, highlighting the need for new molecular targets and therapies. Nuclear receptor HNF4
Autor:
Cory Abate-Shen, Amir Lankarani, Matteo Di Bernardo, Michael M. Shen, Rivka L. Shoulson, Soonbum Park, Lijie Rong, Tomasz Owczarek, Talal Syed, Hikmat Al-Ahmadie, David B. Solit, James M. McKiernan, Chee-Wai Chua, Prithi Chakrapani, Jaime Y. Kim
Publikováno v:
Cancer Res
To study the progression of bladder cancer from non–muscle-invasive to muscle-invasive disease, we have developed a novel toolkit that uses complementary approaches to achieve gene recombination in specific cell populations in the bladder urotheliu
Autor:
Toshiyuki Takehara, Kimio Yonesaka, Hitomi Sakai, Koji Haratani, Hidetoshi Hayashi, Kazuko Sakai, Hisato Kawakami, Kazuhiko Nakagawa, Takeshi Teramura, Shinichiro Suzuki, Kazuto Nishio, Ryoji Kato, Junko Tanizaki
Publikováno v:
Clinical Cancer Research. 27:5697-5707
Purpose: Treatment with KRASG12C inhibitors such as sotorasib can produce substantial regression of tumors in some patients with non–small cell lung cancer (NSCLC). These patients require alternative treatment after acquiring resistance to the inhi
Autor:
Yashaswi Shrestha, Ronald Herbst, Rajiv Raja, Maria Libera Ascierto, Michael Oberst, Philip Martin, Melissa de los Reyes, Nabendu Pore, Raymond Rothstein, John Meekin, Ashok K. Gupta, Melanie M. Frigault, Stephen Blackmore, Ina Bisha, Nathan Standifer, Shaad Essa Abdullah, Theresa Proia, Matthew Griffin, Phillip A. Dennis, Rebecca A. Halpin, Song Wu, Ricardo J Miragaia, Kathy Mulgrew, J. Carl Barrett, Maria Jure-Kunkel
Publikováno v:
Cancer Discovery. 11:2828-2845
Mutations in the STK11 (LKB1) gene regulate resistance to PD-1/PD-L1 blockade. This study evaluated this association in patients with nonsquamous non–small cell lung cancer (NSCLC) enrolled in three phase I/II trials. STK11 mutations were associate
Autor:
Bruce A. Littlefield, Elodie Modave, Amy Weaver, Bram Boeckx, Diether Lambrechts, Agnieszka Wozniak, Patrick Schöffski
Publikováno v:
Clinical Cancer Research. 27:3106-3115
Purpose:A randomized phase III study evaluated the efficacy of eribulin versus dacarbazine in patients with advanced liposarcoma and leiomyosarcoma. Improved overall survival (OS) led to approval of eribulin for liposarcoma, but not for leiomyosarcom
Autor:
Satoshi Yoda, Wafa Malik, Adam Langenbucher, Justin F. Gainor, Sai-Hong Ignatius Ou, Kylie Prutisto-Chang, Ramin Sakhtemani, Jennifer L Peterson, Aaron N. Hata, Alexander Drilon, Andrew Do, Jessica J. Lin, Adam J. Schoenfeld, Viola W. Zhu, Ted William Johnson, Jochen K. Lennerz, Lecia V. Sequist, Noura J. Choudhury, Ibiayi Dagogo-Jack, Subba R. Digumarthy, Christina Falcon, Charlotte E. Lee, Alice T. Shaw, Michael S. Lawrence, Beow Y. Yeap, Jennifer S. Temel, Harper Hubbeling
Publikováno v:
Clin Cancer Res
Purpose: Current standard initial therapy for advanced, ROS proto-oncogene 1, receptor tyrosine kinase fusion (ROS1)-positive (ROS1+) non–small cell lung cancer (NSCLC) is crizotinib or entrectinib. Lorlatinib, a next-generation anaplastic lymphoma
Autor:
Kristan H. Cleveland, Abdullah Shamim, Sherry Liang, Ying Huang, Mengbing Chen, Cyrus Parsa, Bradley T. Andresen, Ayaz Shahid, Robert Orlando
Publikováno v:
Cancer Prev Res (Phila)
Skin cancer is the most common malignancy worldwide and is rapidly rising in incidence, representing a significant public health challenge. The β-blocker, carvedilol, has shown promising effects in preventing skin cancer. However, as a potent β-blo
Autor:
Eva Ciruelos, Ingrid A. Mayer, Chong Ma, Sibylle Loibl, Dejan Juric, Albert Reising, Hope S. Rugo, Michelle Miller, Hiroji Iwata, Mario Campone, Pierfranco Conte, Fabrice Andre, Naveen Babbar, Monica Arnedos
Publikováno v:
Cancer Research. 81:PD2-06
Introduction: The PI3K pathway is often hyperactivated in cancer as a result of an altered PI3K isoform and/or loss of phosphatase and tensin homolog function. Approximately 40% of patients (pts) with hormone receptor-positive (HR+), human epidermal
Autor:
Emad A. Rakha, David M. Heery, Cíntia J. Monteiro, Kartikeya Bhardwaj, Nigel P. Mongan, Wilbert Zwart, Mansour Alsaleem, Steffi Oesterreich, Takaaki Fujii, Ian O. Ellis, Andrew R. Green, Stacey E. P. Joosten, Sasagu Kurozumi, Ken Shirabe, Simon J Johnston
Publikováno v:
Cancer Research. 81:PS6-11
Invasive lobular carcinoma (ILC) accounts for 10-15% of primary breast cancer and is typically ER+ and ERBB2 non-amplified. There is preclinical evidence that somatic ERBB2 mutation may provide an alternative and tractable mechanism for upregulation
Autor:
Jianying Zhou, Tejaswini P. Reddy, Hongbin Wang, Stacy L. Moulder, Wei Qian, Roberto R. Rosato, Jenny C. Chang, Helen Piwnica-Worms, Liliana Guzman
Publikováno v:
Cancer Research. 81:PS11-17
Metaplastic breast cancer (MpBC) is a rare subset accounting for less than 1% of all breast cancers. MpBC exhibits the worst prognosis in comparison to triple-negative breast cancer (TNBC) with a dismal poor survival rate in patients with metastatic